You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 116 No. 8, August 1981 TABLE OF CONTENTS
  Archives
  •  Online Features
  Correspondence and Brief Communications
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Use of Hickman Right Atrial Catheter for Vascular Access in Marrow Transplant Recipients

GIAN FRANCO ADAMI, MD; ANDREA BACIGALUPO, MD; UMBERTO BONALUMI, MD; MARIA TERESA VAN LINDT, MD; FRANCESCO GRIFFANTI-BARTOLI, MD
Genoa, Italy

Arch Surg. 1981;116(8):1099.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.–Hickman right atrial catheters (HRAC) were placed in 40 patients (aged 10 to 44 years) with acute leukemia or aplastic anemia, who were eligible for bone marrow transplantation (BMT).1 The internal diameter of the silicone rubber catheters was 1.6 mm. Prior to insertion, catheters were washed with soap and water and sterilized for 30 minutes at 121 °C. The tip of the catheter was radiologically guided to the right atrium via the cephalic vein (31 cases) dissected in the deltopectoral groove, or in the internal jugular vein (nine cases). The extravascular portion of the catheter was placed in a subcutaneous channel2 on the chest wall. Blood was drawn drawn daily for routine tests through the catheter; total parenteral nutrition (TPN) compounds, chemotherapy drugs, hydration solutions, antibiotics, and blood products were all administrated through the HRAC. However, when blood products were infused, use of TPN solutions . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.